<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: Recent studies have suggested that both laparoscopic and open anti-reflux surgery may produce regression of Barrett's mucosa </plain></SENT>
<SENT sid="1" pm="."><plain>MATERIAL AND METHODS;: We reviewed 21 patients (13M: 8F, mean age 46.7±3.18 years) with documented <z:hpo ids='HP_0002020'>Gastroesophageal Reflux Disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e>) and Non-dysplastic <z:hpo ids='HP_0100580'>Barrett's esophagus</z:hpo> (15 patients ?3 cm segment, 6 patients &lt; 3 cm segment) on long term <z:chebi fb="0" ids="49200">proton pump inhibitor</z:chebi> therapy who underwent laparoscopic Nissen fundoplication (LNF) between 1993 and 2000 </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients had undergone pre and yearly postoperative upper GI endoscopy with 4 quadrant biopsies every 2 cm </plain></SENT>
<SENT sid="3" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients also underwent pre- and 6 months postoperative 24-hr pH study, esophageal manometry, SF36, and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> symptom score </plain></SENT>
<SENT sid="4" pm="."><plain>The mean duration of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> symptoms was 8.4±1.54 years pre-operative </plain></SENT>
<SENT sid="5" pm="."><plain>The mean follow-up after surgery was 39±6.32 months </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: Postoperatively, there was significant improvement in reflux symptom score (37.5 ± 3.98 points versus 8.7 ± 2.46 points, P = 0.0001), % <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> in 24 hr (26.5 ± 3.91% versus 2.1 ± 0.84%, P&lt; 0.0001) and an increase in lower esophageal sphincter pressure (3.71 ± 1.08 mmHg versus 12.29 ± 1.34 mmHg, P = 0.0053) </plain></SENT>
<SENT sid="7" pm="."><plain>Complete or partial regression of Barrett's mucosa occurred in 9 patients </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> patients with complete regression had &lt;4 cm segment of Barrett's </plain></SENT>
<SENT sid="9" pm="."><plain>Progression or <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> transformation was not observed in any of the patients </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: LNF in patients with <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> results in significant control of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">GERD</z:e> symptoms </plain></SENT>
<SENT sid="11" pm="."><plain>LNF can prevent progression of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and in patients with Barrett's &lt;4 cm may lead to complete regression </plain></SENT>
</text></document>